Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.43 |
| ▸ | JAK2 | O60674 | 6/20 | 0.39 |
| ▸ | JAK3 | P52333 | 5/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.36 |
| ▸ | MTOR | P42345 | 7/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2789279 | 0.92 | PIK3CA (0.43) | KCNH2JAK2JAK3PIK3CAMTOR | |
| SCHEMBL751199 | 0.89 | KCNH2 (0.45) | KCNH2JAK2JAK3PIK3CAMTOR | |
| SCHEMBL751893 | 0.78 | MTOR (0.47) | KCNH2JAK2JAK3PIK3CAMTOR | |
| SCHEMBL11030991 | 0.77 | KCNH2 (0.46) | KCNH2JAK2JAK3PIK3CAMTOR | |
| SCHEMBL11026266 | 0.76 | KCNH2 (0.45) | KCNH2JAK2JAK3PIK3CAMTOR | |
| SCHEMBL2785811 | 0.74 | PIK3CA (0.48) | PIK3CAMTOR | |
| SCHEMBL752822 | 0.73 | FYN (0.45) | KCNH2PIK3CAMTORKDM4ESMN1; SMN2 | |
| SCHEMBL751467 | 0.73 | PIK3CA (0.45) | PIK3CAMTOR | |
| SCHEMBL752419 | 0.73 | MTOR (0.47) | PIK3CAMTOR | |
| SCHEMBL2791183 | 0.73 | FYN (0.48) | KCNH2JAK2JAK3PIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430013-B1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC (US) | 2014-10-15 | — | — | EP | claimed |
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | AMGEN INC. (US) | 2012-07-26 | — | — | US | claimed |
| EP-2430013-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | Amgen, Inc (US) | 2012-03-21 | — | — | EP | claimed |
| EP-2430013-B1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC (US) | 2014-10-15 | — | — | EP | disclosed |
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | AMGEN INC. (US) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | PIK3CA, PIKFYVE, PIK3CD | KCNH2 2938/4885JAK2 312/4885JAK3 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.